Anti-CD20 therapies for multiple sclerosis: current status and future perspectives

Area of Science:

• Neuroimmunology
• Immunotherapy
• Central Nervous System Disorders

Background:

• Multiple sclerosis (MS) is a chronic CNS disease causing progressive disability.
• Recent advances highlight the critical role of B cells in MS pathogenesis.
• This necessitates a re-evaluation of MS immune pathophysiology.

Purpose of the Study:

• To provide an updated overview of B-cell involvement in MS.
• To review the efficacy and safety of anti-CD20 therapies in MS.
• To discuss future perspectives for B-cell-targeted treatments.

Main Methods:

• Review of randomized controlled trials and observational studies.
• Analysis of data on anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab).
• Discussion of current literature on B-cell pathophysiology in MS.

Main Results:

• Anti-CD20 therapies show significant efficacy and a favorable safety profile in MS.
• These treatments have expanded therapeutic options for relapsing and progressive MS.
• B cells are recognized as key players, interacting with other immune cells in MS.

Conclusions:

• B-cell depletion is a validated therapeutic strategy for MS.
• Anti-CD20 therapies represent a major advancement in MS management.
• Further research into B-cell targeted therapies holds promise for future MS treatments.